Search Within

Fernando Costa Santini

Formats
  1. Journal Article (9)
  2. Meeting Abstract (9)
  3. Review (4)
Groups
  1. Department of Medicine (19)
  2. Solid Tumor Oncology Division (19)
  3. Thoracic Oncology (19)
  4. Weinberg Fellows (12)
  5. GME, Medicine (9)
  6. GSK Faculty (9)

More Groups

People
  1. Alexander Drilon (9)
  2. Mark Kris (8)
  3. Jamie Chaft (6)
  4. Juliana Eng (6)
  5. Bob Li (5)
  6. Charles Rudin (5)

More People

Years
  1. 2024 (5)
  2. 2023 (5)
  3. 2022 (4)
  4. 2021 (1)
  5. 2018 (2)
  6. 2017 (5)
Publications
  1. Journal of Clinical Oncology (4)
  2. Lung Cancer (2)
  3. Annals of Oncology (1)
  4. Cancer Immunology Research (1)
  5. Cancer Research (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Elsevier Inc. (4)
  3. American Association for Cancer Research (3)
  4. Elsevier Ireland Ltd. (2)
  5. Sage Publications (2)
  6. Dove Medical Press Ltd (1)

More Publishers

Results (22)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Meeting Abstract

    Loong, H.; Goto, K.; Solomon, B.; Park, K.; PeĢrol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Exploratory analysis of ctDNA and imaging response in the phase I/II CHORUS study of canakinumab with chemoradiation and durvalumab consolidation for stage Ill NSCLC
    Meeting Abstract

    Shaverdian, N.; Offin, M.; Charalambous, K.; Gelblum, D.; Santini, F.; Boe, L. A.; Shepherd, A. F.; Gewanter, R. M.; Shin, J. Y.; Rimner, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
    Journal Article

    Choudhury, N. J.; Lai, W. V.; Makhnin, A.; Heller, G.; Eng, J.; Li, B.; Preeshagul, I.; Santini, F. C.; Offin, M.; Ng, K.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer
    Journal Article

    Liu, S. Y.; Erazo, T.; Jee, J.; Arfe, A.; Gupta, A.; Pike, L. R. G.; Santini, F. C.; Daly, B.; Schoenfeld, A.; Eichholz, J.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer
    Journal Article

    Thummalapalli, R.; Bernstein, E.; Herzberg, B.; Li, B. T.; Iqbal, A.; Preeshagul, I.; Santini, F. C.; Eng, J.; Ladanyi, M.; Yang, S. R.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Phase II study of cabozantinib in patients with MET-altered lung cancers
    Meeting Abstract

    Harada, G.; Santini, F. C.; Repetti, R. W.; Chang, J.; Yang, S. R.; Lin, Y. T.; Moses, K. A.; Falcon, C.; Wilhelm, C. J.; Goldstein, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Brazilian expert consensus for NTRK gene fusion testing in solid tumors
    Review

    de Macedo, M. P.; Toledo Nascimento, E. C.; Soares, F. A.; Costa Santini, F.; D'Almeida Costa, F.; Werneck da Cunha, I.; Ramella Munhoz, R.; De Marchi, P.; Carnier Jorge, T. W.; Ramos Moreira Leite, K.
    Clinical Pathology (2023)

    Fulltext@MSK | Save
  • Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer
    Meeting Abstract

    Arbour, K. C.; Thummalapalli, R.; Bernstein, E.; Herzberg, B.; Li, B. T.; Iqbal, A.; Santini, F. C.; Eng, J.; Ladanyi, M.; Yang, S. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2 -mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Liu, S. Y.; Jee, J.; Santini, F. C.; Schoenfeld, A. J.; Eichholz, J.; Johnson, K.; Martinez, A.; Guo, J.; Riaz, N.; Lee, N. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save